Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Surgery International
Published in: Pediatric Surgery International 12/2016

01-12-2016 | Original Article

Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation

Authors: Amei Schweigert, Carmen Fischer, Doris Mayr, Dietrich von Schweinitz, Roland Kappler, Jochen Hubertus

Published in: Pediatric Surgery International | Issue 12/2016

Login to get access

Abstract

Purpose

The Wnt/β-catenin pathway is known to be crucial for the regulation of embryogenesis and cell differentiation, and its constitutive activation is associated with a wide range of malignancies. There are two major principles for an activated Wnt/β-catenin pathway. The first is caused by the failure of the destruction complex, mainly due to the decreased expression of the tumor suppressor gene adenomatous polyposis coli (APC); the second is the mutation of the β-catenin (CTNNB1) protein itself. Wilms tumors (WTs) are also thought to be malignancies with a high rate of Wnt/β-catenin pathway activation. The aim of this study was to analyze a large cohort of WT for activated Wnt/β-catenin pathway.

Methods

The transcription of axis inhibition protein 2 (AXIN2) and APC was analyzed by real-time PCR. Expression was compared with those in healthy renal tissues as a control. Methylation status of the APC promoter was measured by pyrosequencing and correlated with APC expression. Finally, the mutations of CTNNB1 itself were detected by Sanger sequencing.

Results

The analysis was done in a cohort of 103 WTs, treated in our institution. There was a significant overexpression of AXIN2 in WTs (P < 0.0001), with 33 (32 %) tumors showing higher expression (median + 3× SD) than normal kidney tissue. In contrast, the expression of APC as well as its promoter methylation did not differ from control (P = 0.78; P = 0.82). Finally, there were only seven (6.8 %) mutations detectable in CTNNB1, and five out of seven were seen in WTs with AXIN2 overexpression.

Conclusion

The finding that AXIN2, one of the major Wnt target genes, is overexpressed in our cohort of WTs, is indicative for the activation of the Wnt/β-catenin pathway. However, neither the alteration of APC nor frequent CTNNB1 mutations were seen in our analyses. Therefore, other mechanisms might be responsible for the common activation of the Wnt/β-catenin pathway.
Literature
1.
Breslow N et al (1988) Age distribution of Wilms’ tumor: report from the National Wilms’ Tumor Study. Cancer Res 48(6):1653–1657PubMed
2.
3.
4.
Li CM et al (2002) Gene expression in Wilms’ tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160(6):2181–2190CrossRefPubMedPubMedCentral
5.
6.
Rakheja D et al (2014) Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun 2:4802CrossRefPubMedPubMedCentral
7.
Ruteshouser EC, Robinson SM, Huff V (2008) Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47(6):461–470CrossRefPubMedPubMedCentral
8.
Wittmann S et al (2008) New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 47(5):386–395CrossRefPubMed
9.
Astuti D et al (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet 357(9263):1181–1182CrossRefPubMed
10.
Williams RD et al (2010) Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms’ tumor. Clin Cancer Res 16(7):2036–2045CrossRefPubMed
11.
12.
13.
Wegert J et al (2015) Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27(2):298–311CrossRefPubMed
14.
Bjornsson HT et al (2007) Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst 99(16):1270–1273CrossRefPubMed
15.
Hubertus J et al (2011) Altered expression of imprinted genes in Wilms tumors. Oncol Rep 25(3):817–823CrossRefPubMed
16.
Zitzmann F et al (2014) Frequent hypermethylation of a CTCF binding site influences Wilms tumor 1 expression in Wilms tumors. Oncol Rep 31(4):1871–1876PubMed
17.
18.
Cardoso LC et al (2013) WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms’ tumor. Oncol Rep 29(1):315–320PubMed
19.
Perotti D et al (2013) Is Wilms tumor a candidate neoplasia for treatment with WNT/beta-catenin pathway modulators?—a report from the renal tumors biology-driven drug development workshop. Mol Cancer Ther 12(12):2619–2627CrossRefPubMed
20.
21.
22.
Valenta T, Lukas J, Korinek V (2003) HMG box transcription factor TCF-4’s interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells. Nucleic Acids Res 31(9):2369–2380CrossRefPubMedPubMedCentral
23.
He TC et al (1998) Identification of c-MYC as a target of the APC pathway. Science 281(5382):1509–1512CrossRefPubMed
24.
de Kraker J et al (2004) Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms’ tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 364(9441):1229–1235CrossRefPubMed
25.
26.
Koch A et al (1999) Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 59(2):269–273PubMed
27.
Esteller M et al (2000) Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 60(16):4366–4371PubMed
28.
Sparks AB et al (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58(6):1130–1134PubMed
29.
Park WS et al (1999) Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 59(17):4257–4260PubMed
30.
31.
32.
Kispert A, Vainio S, McMahon AP (1998) Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. Development 125(21):4225–4234PubMed
33.
Koesters R et al (1999) Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms’ tumors. Cancer Res 59(16):3880–3882PubMed
34.
Bernkopf DB, Hadjihannas MV, Behrens J (2015) Negative-feedback regulation of the Wnt pathway by conductin/axin2 involves insensitivity to upstream signalling. J Cell Sci 128(1):33–39CrossRefPubMed
35.
36.
37.
Wissmann C et al (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201(2):204–212CrossRefPubMed
38.
Gumz ML et al (2007) Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13(16):4740–4749CrossRefPubMed
39.
Zirn B et al (2006) Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer 45(6):565–574CrossRefPubMed
Metadata
Title
Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation
Authors
Amei Schweigert
Carmen Fischer
Doris Mayr
Dietrich von Schweinitz
Roland Kappler
Jochen Hubertus
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Surgery International / Issue 12/2016
Print ISSN: 0179-0358
Electronic ISSN: 1437-9813
DOI
https://doi.org/10.1007/s00383-016-3970-6

Other articles of this Issue 12/2016

Pediatric Surgery International 12/2016 Go to the issue

Original Article

Decreased Desmin expression in the developing diaphragm of the nitrofen-induced congenital diaphragmatic hernia rat model

Original Article

Blockade of the renin–angiotensin system prevents acute and immunologically relevant colitis in murine models

Original Article

Open versus laparoscopic approach for intestinal malrotation in infants and children: a systematic review and meta-analysis

Original Article

Fenofibrate reduces intestinal damage and improves intestinal recovery following intestinal ischemia–reperfusion injury in a rat

Original Article

Accelerated intestinal epithelial cell turnover after bowel resection in a rat is correlated with inhibited hedgehog signaling cascade

Original Article

The administration of ghrelin improved hepatocellular injury following parenteral feeding in a rat model of short bowel syndrome